Nantahala Capital Management, LLC
About Nantahala Capital Management, LLC’s 13F portfolio
Nantahala Capital Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Nantahala Capital Management, LLC reported $1.7B across 132 US-listed positions (). Its largest position is BANCORP INC DEL (TBBK) at 4.7% of the reported book, and its ten biggest holdings make up 27% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: TBBK BANCORP INC DEL | $44.26 −1.97% | 4.7% | 1.2M | $77.7M |
| 2 | NASDAQ: BVS BIOVENTUS INC | $9.95 −6.31% | 3.4% | 6.0M | $56.6M |
| 3 | NYSE: HGV HILTON GRAND VACATIONS INC | $44.65 −3.88% | 3.3% | 1.0M | $54.1M |
| 4 | NASDAQ: SVRA SAVARA INC | $5.21 +10.38% | 2.6% | 7.0M | $43.0M |
| 5 | NASDAQ: ETON ETON PHARMACEUTICALS INC | $61.36 −1.02% | 2.6% | 1.2M | $42.6M |
| 6 | NASDAQ: AMRX AMNEAL PHARMACEUTICALS INC | $21.39 −2.24% | 2.4% | 2.3M | $39.3M |
| 7 | NASDAQ: EOLS EVOLUS INC | $7.00 −0.99% | 2.3% | 5.6M | $38.9M |
| 8 | NASDAQ: AVTX AVALO THERAPEUTICS INC | $6.75 +0.75% | 2.1% | 1.9M | $34.4M |
| 9 | NASDAQ: LBRX LB PHARMACEUTICALS INC | $40.04 −0.05% | 2.1% | 1.1M | $34.2M |
| 10 | NASDAQ: AVR ANTERIS TECHNOLOGIES GLOBAL | $5.09 −2.30% | 2.0% | 3.4M | $33.3M |
| 11 | NASDAQ: ABEO ABEONA THERAPEUTICS INC | $2.45 −10.26% | 1.9% | 5.1M | $31.7M |
| 12 | NASDAQ: PTON PELOTON INTERACTIVE INC | $5.07 −5.23% | 1.8% | 5.1M | $30.2M |
| 13 | NASDAQ: ESTA ESTABLISHMENT LABS HLDGS INC | $69.61 −1.68% | 1.7% | 336K | $28.8M |
| 14 | NYSE American: XTNT XTANT MED HLDGS INC | $0.22 +5.00% | 1.7% | 68.4M | $28.8M |
| 15 | NASDAQ: JACK JACK IN THE BOX INC | $13.80 −6.69% | 1.7% | 1.7M | $27.3M |
| 16 | NASDAQ: GOGO GOGO INC | $2.78 −5.12% | 1.6% | 8.7M | $27.0M |
| 17 | NYSE: IMAX IMAX CORP | $46.18 −1.30% | 1.6% | 658K | $26.2M |
| 18 | NASDAQ: ZVRA ZEVRA THERAPEUTICS INC | $9.07 −2.26% | 1.6% | 1.8M | $25.8M |
| 19 | NASDAQ: TITN TITAN MACHY INC | $20.77 −2.53% | 1.4% | 1.1M | $23.9M |
| 20 | NASDAQ: RMR RMR GROUP INC | $16.33 −4.00% | 1.4% | 1.1M | $23.6M |
| 21 | NASDAQ: FOSL FOSSIL GROUP INC | $7.60 −8.65% | 1.4% | 5.5M | $22.8M |
| 22 | NASDAQ: FOXF FOX FACTORY HLDG CORP | $16.90 −1.97% | 1.3% | 1.3M | $22.2M |
| 23 | NASDAQ: MLYS MINERALYS THERAPEUTICS INC | $14.16 +2.76% | 1.3% | 820K | $22.1M |
| 24 | NASDAQ: RDNW RIDENOW GROUP INC | $4.42 −1.67% | 1.3% | 3.3M | $21.8M |
| 25 | NASDAQ: QURE UNIQURE NV | $20.23 −0.34% | 1.3% | 456K | $21.0M |
Showing 1–25 of 132 positions on this page reported in this 13F.
- Healthcare59%
- Consumer Cyclical16%
- Financial Services6.2%
- Communication Services4.1%
- Industrials3.0%
- Real Estate2.6%
- Consumer Defensive2.4%
- Technology1.6%
- Basic Materials0.8%
- AddedAVTXAVALO THERAPEUTICS INC+50.8%$34.4M
- AddedABEOABEONA THERAPEUTICS INC+2.5%$31.7M
- AddedJACKJACK IN THE BOX INC+12.1%$27.3M
- AddedIMAXIMAX CORP+27.6%$26.2M
- AddedFOSLFOSSIL GROUP INC+1.9%$22.8M
- AddedQUREUNIQURE NV+92.2%$21.0M
- AddedAURAAURA BIOSCIENCES INC+39.4%$21.0M
- AddedAGMBAGOMAB THERAPEUTICS NV+30.7%$20.4M
- AddedFULCFULCRUM THERAPEUTICS INC+79.5%$20.0M
- AddedBNTCBENITEC BIOPHARMA INC+3.5%$19.9M
- ReducedTBBKBANCORP INC DEL−10.2%$77.7M
- ReducedBVSBIOVENTUS INC−2.0%$56.6M
- ReducedHGVHILTON GRAND VACATIONS INC−31.7%$54.1M
- ReducedSVRASAVARA INC−5.0%$43.0M
- ReducedAMRXAMNEAL PHARMACEUTICALS INC−20.2%$39.3M
- ReducedEOLSEVOLUS INC−12.2%$38.9M
- ReducedAVRANTERIS TECHNOLOGIES GLOBAL−38.8%$33.3M
- ReducedPTONPELOTON INTERACTIVE INC−57.4%$30.2M
- ReducedESTAESTABLISHMENT LABS HLDGS INC−59.7%$28.8M
- ReducedGOGOGOGO INC−2.1%$27.0M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | — Eagle Pharmaceuticals, Inc. | 13G | 38.1% | 4.9M | Filed 14 AUG 2025 |
| 2 | TELA TELA Bio, Inc. | 13G | 14.5% · 2 classes | 6.5M | Filed 13 NOV 2026 |
| 3 | RACC Research Alliance Corp III | 13G | 14.1% | 1.1M | Filed 07 OCT 2026 |
| 4 | GUTS Fractyl Health, Inc. | 13G | 10.0% · 2 classes | 13.3M | Filed 14 NOV 2025 |
| 5 | COCH ENVOY MEDICAL, INC. | 13G | 10.0% | 7.7M | Filed 15 MAY 2026 |
| 6 | AZTR AZITRA, INC. | 13G | 10.0% | 6.5M | Filed 14 AUG 2026 |
| 7 | FOSL FOSSIL GROUP, INC. | 13G | 10.0% · 2 classes | 5.9M | Filed 15 MAY 2026 |
| 8 | ABEO ABEONA THERAPEUTICS INC. | 13G | 10.0% · 2 classes | 5.8M | Filed 15 MAY 2026 |
| 9 | QNCX Quince Therapeutics, Inc. | 13G | 10.0% · 2 classes | 5.6M | Filed 14 NOV 2025 |
| 10 | AEON AEON Biopharma, Inc. | 13G | 10.0% | 5.0M | Filed 13 NOV 2026 |
| 11 | ELUT Elutia Inc. | 13G | 10.0% | 4.1M | Filed 13 FEB 2026 |
| 12 | APYX APYX MEDICAL CORPORATION | 13G | 10.0% | 4.1M | Filed 13 FEB 2026 |
| 13 | UNCY Unicycive Therapeutics, Inc. | 13G | 10.0% · 2 classes | 2.8M | Filed 14 AUG 2026 |
| 14 | XFOR X4 PHARMACEUTICALS, INC | 13G | 10.0% | 2.2M | Filed 14 NOV 2025 |
| 15 | DRIO DarioHealth Corp. | 13G | 10.0% · 2 classes | 979K | Filed 13 NOV 2026 |
| 16 | EDSA EDESA BIOTECH, INC. | 13G | 10.0% | 856K | Filed 13 FEB 2026 |
| 17 | PHGE BiomX Inc. | 13G | 10.0% · 2 classes | 157K | Filed 13 FEB 2026 |
| 18 | ADCT ADC Therapeutics SA | 13G | 9.7% | 12.3M | Filed 14 AUG 2026 |
| 19 | AVTX AVALO THERAPEUTICS, INC. | 13G | 9.4% | 1.2M | Filed 14 NOV 2025 |
| 20 | ASRT ASSERTIO HOLDINGS, INC. | 13G | 9.4% · 2 classes | 8.9M | Filed 14 NOV 2024 |
| 21 | HAIN The Hain Celestial Group, Inc. | 13G | 9.4% · 2 classes | 8.5M | Filed 15 MAY 2026 |
| 22 | BVS BIOVENTUS INC. | 13G | 9.0% | 6.0M | Filed 13 FEB 2026 |
| 23 | EOLS EVOLUS, INC. | 13G | 8.8% | 5.7M | Filed 14 NOV 2025 |
| 24 | RDNW RumbleOn, Inc. | 13G | 8.7% | 3.1M | Filed 14 NOV 2024 |
| 25 | FULC FULCRUM THERAPEUTICS, INC. | 13G | 8.6% · 2 classes | 6.6M | Filed 13 NOV 2026 |
Showing 1–25 of 45 disclosed stakes. 7 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Nantahala Capital Management, LLC’s 13F portfolio
Nantahala Capital Management, LLC’s $1.7B 13F book is spread across 132 reported positions and is moderately diversified, the ten largest names accounting for 27%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are TBBK, BVS, HGV, SVRA and ETON, led by BANCORP INC DEL (TBBK) at 4.7% of the portfolio. The heaviest sector exposure is Healthcare (59%), then Consumer Cyclical (16%).
What Nantahala Capital Management, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Nantahala Capital Management, LLC was a net seller: it opened 22 new positions and added to 25 more, while trimming 39 and closing 20 outright. Against a 132-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was AVALO THERAPEUTICS INC (AVTX), and its biggest reduction was BANCORP INC DEL (TBBK).
What a 13F does and doesn’t reveal
A 13F captures only Nantahala Capital Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Nantahala Capital Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Nantahala Capital Management, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Nantahala Capital Management, LLC's page?
It reflects Nantahala Capital Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Nantahala Capital Management, LLC files its next quarterly report, this page refreshes automatically.
Can I see Nantahala Capital Management, LLC's complete list of holdings?
This page highlights Nantahala Capital Management, LLC's largest positions rather than all 132 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Nantahala Capital Management, LLC's filings.
Does a 13F show everything Nantahala Capital Management, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Nantahala Capital Management, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Nantahala Capital Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

